Intas Pharmaceuticals to go for $4-billion deals in a month

Teva's units in Europe and Mallinckrodt's US generic business among the planned bids

Ahmedabad-based Intas Pharmaceuticals had emerged as the dark horse last October when it acquired the generic business of Actavis in the UK and Ireland for Rs 5,100 crore ($732 million) from Teva. 

Intas beat global giants Mylan and Novartis, besides domestic rival Aurobindo Pharma, to the deal.

In less than a year, Intas will be bidding for three assets worth $4 billion by mid-October. This would be the biggest bet by an Indian pharma overseas. Two of these three assets are Teva’s units in Europe. 

The world’s biggest generic maker is struggling with $40 billion debt following the acquisition of